MedTrace Logo

Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing

NCT00156533 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-11-20

Study results available
· View outcomes & findings →

Summary

We want to assess whether "how and when" one takes sleep medication results in similar or different outcomes with respect to symptom relief. We also want to know whether taking medication for a period of time provides continued benefit once the medication is stopped.

Conditions

  • Insomnia
  • Primary Insomnia
  • Psychophysiologic Insomnia

Interventions

DRUG

Zolpidem

10 mg of Zolpidem

DRUG

Sugar Pill

Sponsors & Collaborators

  • Sanofi-Synthelabo

    collaborator INDUSTRY

  • University of Rochester

    lead OTHER

Principal Investigators

  • Michael L Perlis, Ph.D. · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156533 on ClinicalTrials.gov